WEBINAR: The Promise of Liquid Biopsy Application to Cancer Disease Diagnostics and Therapeutic Monitoring – Are we there yet?”

Circulating cell free DNA as a surrogate sample type for effective diagnostics has remained an area of significant interest. ctDNA has been demonstrated to mirror the tumor mutational landscape and has the potential to monitor mutational changes from therapy over time. This webinar brings together academic, clinical and industry experts in the ctDNA field describing the promises and challenges of liquid biopsy in disease management.

 

We’re committed to your privacy. SeraCare will not share or sell your data. View our privacy policy below for details.